key: cord-0792764-pcrewvvb
authors: Sweid, Ahmad; Hammoud, Batoul; Bekelis, Kimon; Missios, Symeon; Tjoumakaris, Stavropoula I; Gooch, Michael R; Herial, Nabeel A; Zarzour, Hekmat; Romo, Victor; DePrince, Maureen; Rosenwasser, Robert H; Jabbour, Pascal
title: Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019
date: 2020-06-26
journal: Int J Stroke
DOI: 10.1177/1747493020937189
sha: f83b5a78a64abf9f588da852736e8b2f165ddd9c
doc_id: 792764
cord_uid: pcrewvvb

BACKGROUND: The coronavirus disease 2019 is associated with neurological manifestations including stroke. OBJECTIVES: We present a case series of coronavirus disease 2019 patients from two institutions with acute cerebrovascular pathologies. In addition, we present a pooled analysis of published data on large vessel occlusion in the setting of coronavirus disease 2019 and a concise summary of the pathophysiology of acute cerebrovascular disease in the setting of coronavirus disease 2019. METHODS: A retrospective study across two institutions was conducted between 20 March 2020 and 20 May 2020, for patients developing acute cerebrovascular disease and diagnosed with coronavirus disease 2019. We performed a literature review using the PubMed search engine. RESULTS: The total sample size was 22 patients. The mean age was 59.5 years, and 12 patients were female. The cerebrovascular pathologies were 17 cases of acute ischemic stroke, 3 cases of aneurysm rupture, and 2 cases of sinus thrombosis. Of the stroke and sinus thrombosis patients, the mean National Institute of Health Stroke Scale was 13.8 ± 8.0, and 16 (84.2%) patients underwent a mechanical thrombectomy procedure. A favorable thrombolysis in cerebral infarction score was achieved in all patients. Of the 16 patients that underwent a mechanical thrombectomy, the mortality incidence was five (31.3%). Of all patients (22), three (13.6%) patients developed hemorrhagic conversion requiring decompressive surgery. Eleven (50%) patients had a poor functional status (modified Rankin Score 3–6) at discharge, and the total mortality incidence was eight (36.4%). CONCLUSIONS: Despite timely intervention and favorable reperfusion, the mortality rate in coronavirus disease 2019 patients with large vessel occlusion was high in our series and in the pooled analysis. Notable features were younger age group, involvement of both the arterial and venous vasculature, multivessel involvement, and complicated procedures due to the clot consistency and burden.

In six months, the number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases exceeded six million, with more than 360,000 deaths. The World Health Organization named the disease the coronavirus disease 2019 (COVID- 19) and declared it a pandemic on 11 March 2020. 1 Although the lung is the primary affected organ, the virus is neurovirulent and neuroinvasive with a growing recognition of neurological manifestations. The reported incidence of stroke in COVID-19 hospitalized patients is 0.9-2%, 2,3 with an increased incidence in the young. 4 More important than the increased incidence, is the poor outcome and high mortality rate, even with optimal treatment. 5, 6 A recent cross-sectional comparative study from New York identified a 7.5-fold higher rate of ischemic stroke in COVID-19 compared to influenza. 3 In the current pandemic situation, a better understanding of the pathophysiological mechanisms associated with COVID-19 and characterization of cerebrovascular pathologies and outcomes is critical not only to estimate the risk but also to guide decision making. We present a case series of COVID-19 patients from two different health systems presenting with acute cerebrovascular pathologies. We also reviewed the literature to present a comprehensive summary of the SARS-CoV-2-induced factors that are associated with acute cerebrovascular pathologies. In addition, we performed a pooled analysis of published data on large vessel occlusion strokes in the setting of COVID-19.

Institutional review board of Thomas Jefferson University Hospital (12D:534) approved the study protocol and waived the need for informed consent. A retrospective analysis was conducted across two institutions between 20 March and 20 May 2020. Twenty-two patients were identified with the diagnosis of acute cerebrovascular disease and COVID-19 infection. Medical charts were queried for baseline patient characteristics (age, gender), comorbidities (heart disease, lung disease, liver disease, kidney disease, atrial fibrillation, and diabetes mellitus), COVID-19 symptoms (fever, cough, pneumonia), duration between COVID-19 symptoms and the neurological manifestation, cerebrovascular insult (aneurysm rupture, intracranial hemorrhage, and stroke), National Institute of Health Stroke Scale (NIHSS) at presentation, procedure detail (duration from the sheath into sheath out and thrombolysis in cerebral infarction (TICI) score, laboratory results, and mortality.

Additionally, total ischemic stroke admissions, mechanical thrombectomy (MT) procedures, and telestroke consults during the period between 15 March and 30 April 2020 were compared to the mean cases of the previous three years (15 March-30 April 2017 , 2018 , 2019 at Thomas Jefferson University Hospital in one of the institutions, which is a tertiary telestroke referral network.

Lastly , using the PubMed search engine, we performed a literature search on 3 May 2020 with no  time limitations for all articles in English, using different combinations of the terms Coronavirus, COVID,  SARS-CoV-2, ACE2 , stroke, and large vessel occlusion. Abstracts were screened to determine if the study matched our requirements. Then the full-text was read indepth, to determine the correlation between viral infection and stroke, and outcomes of ischemic stroke due to large vessel occlusion in the setting of COVID-19.

We excluded manuscripts that had grouped transient ischemic attack, small vessel occlusion or hemorrhagic stroke with LVO, as it was not possible to identify the details for patients with LVO.

Variables collected for pooled analysis included number of LVO cases, mean age, male gender, NIHSS at admission, number of involved vessels, MT treatment, usage of Solumbra technique (aspiration with retriever), number of attempts to retrieve the clot, TICI 2B/3, symptomatic ischemic or hemorrhagic complications, and mortality.

The total sample size was 22 patients. The mean age was 59.5 AE 16.0 years, and 12 patients were female (54.4%). Twelve (54.4%) of the patients had no significant prior medical history. Ten patients (45.5%) had a cerebrovascular event as the initial manifestation of COVID-19. For patients who were symptomatic of COVID-19, the duration from symptom onset and neurological manifestation was 8.8 AE 4.4 days. The cerebrovascular pathologies were 17 cases of acute ischemic stroke, 3 cases of aneurysm rupture, and 2 cases of sinus thrombosis. Of the stroke and sinus thrombosis patients, the mean NIHSS was 13.8 AE 8.0, and 16 (84.2%) patients underwent a MT procedure within 6 h of symptom onset. Of the 16 patients who underwent MT, 13/16 (81.2%) patients received general endotracheal anesthesia. A Solumbra technique, aspiration plus stentriever, was used in 13/16 (81.2%) to retrieve the clot completely. The mean number of passes was 2.1, and the average procedure duration from groin access to achieving final TICI score was 42.2 AE 36.3 min. Of note, 3/16 (18.8%) of all patients required intracranial stenting as a rescue measure to maintain the vessel patency. A favorable TICI score (!2B/3) was achieved in all patients. The mortality incidence was 5/16 (31.3%). Of all patients (22) , three (13.6%) patients developed hemorrhagic conversion requiring decompressive surgery. Eleven patients (50%) had poor functional status (mRS 3-6) at discharge, and the total mortality incidence was eight (36.3%) ( Table 1) . Laboratory studies showed an elevated D-dimer (3497.4 AE 6754.3 ng/dl), CRP (20.8 AE 37.9 mg/dl), and IL-6 (41.6 AE 62.0 pg/dl).

Vital stroke metrics across a tertiary telestroke network demonstrated a significant decline in AIS admissions by 23% (p ¼ 0.001) and telestroke consults by 48% (p ¼ 0.001) compared to a similar period in previous years. Conversely, MT procedures showed a nonsignificant increase by 50% (p ¼ 0.112) during the same period ( Table 2) .

The result of the pooled analysis of ischemic stroke due to LVO data is presented in Table 3 . In summary, the total sample size was 39 patients. The mean age was 59.4 years with 26 (66.7%) males. The NIHSS at admission was 19.0 with an average of 1.5 involved vessels. 89.7% of the patients underwent MT with the majority (85%) using a Solumbra technique. On average, 2.3 attempts were required to retrieve the clot with 77.1% of cases achieving TICI 2B/3. Notably the complication rate was 15.4%, and the mortality rate was 45.9%.

With the paucity of evidence from large cohorts, it is crucial to maintain vigilance in the management of the neurological manifestations of COVID-19, especially for life-threatening pathologies such as AIS. 2,4,10 Our data demonstrate multiple critical outcomes that are essential to share. First, the mean age of the patients was 59.5 years, which is lower than historical non-COVID stroke series. 11, 12 Half of the patients had a stroke as the initial manifestation of COVID-19, and there was a lag period of nine days between COVID-19 symptoms and the cerebrovascular event. Occlusions The hemorrhagic strokes were due to aneurysm rupture. A PCOM aneurysm (15 mm) ruptured following intense bouts of coughing ( Figure 2 ). The anterior choroidal aneurysm (1.4 mm) ruptured following nine days of sickness due to COVID-19 and nine days International Journal of Stroke, 15 (7) post-partum, and the dissecting PICA ruptured following three days of sickness due to COVID-19. It is crucial to modify treatment for patients with cerebrovascular pathologies. Patients undergoing intracranial stent placement may require tighter control of their P2Y12 levels and blood pressure, while patients undergoing thrombectomy may require prolonged observation or aggressive anticoagulation during the time of peak immune response.

In regards to caseload, we have identified a substantial reduction in total ischemic stroke admissions by 31.8% and telestroke consults by 52.1% compared to previous years, signifying that either the patients are not reporting neurological symptoms due to the fear of the contagion or the stroke incidence has decreased due to other variables. Conversely, MT procedures showed a non-significant increase by 50% during the same period.

It is too early to determine the exact impact of COVID-19 on the incidence of acute cerebrovascular diseases. However, our reported observations provide an opportunity to anticipate and prepare for the challenges in stroke care. The pathophysiology of cerebrovascular disease in COVID-19 patients may be direct or indirect. Direct factors may be related to the SARS-CoV-2 ability to bind to angiotensin-converting enzyme 2 (ACE2) and reduce its downstream effect. The virus is neuroinvasive and neurovirulent, and has a tropism to endothelial cells and cardiomyocytes. 13, 14 Indirect factors are mainly due to a systemic process, including a hyperinflammatory response, hypercoagulable state, and coagulopathy (thromboembolic events and microangiopathy) (Figure 3 ). [15] [16] [17] [18] [19] Additional factors include a prolonged intensive care unit (ICU) stay, which may be associated with hypotension and inadequate cerebral perfusion, stress cardiomyopathy and concomitant reduction in left ventricular ejection fraction, and atrial fibrillation. 3,20

Neurological manifestations caused by the SARS-CoV-2 range from mild symptoms, like anosmia, to severe symptoms, like ischemic stroke or intracerebral hemorrhage. 2, 4, 8, [21] [22] [23] [24] [25] Diagnosis and management of neurological complaints may be more challenging in such an uncharted time due to several reasons including staff allocation, lack of hospital beds, delay in patient presentation, delay in imaging acquisition, and the virtual consultations. Mild symptoms may be the tip of the iceberg, and physicians ought to be vigilant as headaches may be a sign of meningitis, 26 or hemodynamic alterations, or bradypnea may be a sign of brainstem involvement. 27 

Viruses, including coronavirus, can penetrate the central nervous system (CNS) (neuroinvasion), infect neurons and glial cells (neurotropism), and contribute to, or cause neurological disease (neurovirulence). 28 Access may be achieved via two main routes: hematogenous or transneuronal through the olfactory bulb. 27, 29 On the other hand, the hematogenous route involves directly infecting the blood-brain barrier (BBB) or access via a International Journal of Stroke, 15 (7) Trojan such as leukocytes. 27, 30 Human corona virus strains may infect human monocytes/macrophages, 31, 32 murine dendritic cells expressing the human aminopeptidase N, 33 and human endothelial cells of the BBB. 30 As for SARS-CoV-2, detection of the virus in the cerebrospinal fluid of COVID-19 patients has been reported in several publications. 26, 34 ACE2 receptor and angiotensin (1-7) (ANG (1-7) )

The second factor that plays a role in the neurological manifestations of SARV-CoV-2 is the ACE2 receptor. ACE2 is a carboxypeptidase that converts angiotensin II into ANG (1-7), which is an essential component of the renin-angiotensin system. 35 One of the main sites that ANG (1-7) is synthesized and has a downstream effect on is endothelial cells; 36 it stimulates the release of prostaglandin and nitric oxide, 37,38 enhances the metabolic actions of bradykinin, and inhibits smooth muscle cell growth. 39 Additionally, ANG (1-7) enhances the vagal. 40, 41 It also induces a decrease in tyrosine hydroxylase expression, the rate-limiting enzyme in catecholamine biosynthesis, decreasing brain catecholaminergic activity; ANG (1-7) is neuroprotective. 42 In recent rat models, central administration of ANG-(1-7) reduced neurological deficits and infarct size in ischemic stroke. 43, 44 Virus-mediated downregulation of ACE2 has been suggested to underlie the pathology of severe acute respiratory syndrome coronavirus infection. 45, 46 Therefore, binding of SARS-CoV-2 to the ACE2 receptor may similarly inhibit its downstream effect via pathway downregulation or cell lysis, ultimately decreasing ANG (1-7) synthesis. This may counteract its neuroprotective properties and blood pressure autoregulation (increase in sympathetic activity).

The third component is the hypercoagulable state, caused by the virus-induced cytokine storm. The hyper inflammation phase is characterized by the release of inflammatory markers and a cytokine storm. [47] [48] [49] [50] [51] [52] In retrospective studies, critically ill COVID-19 patients had increased proinflammatory cytokines, including IL-2 and TNF-a4, which can upregulate the coagulation system. 2 In a recent Dutch study, there was a 31% incidence of thrombotic complications in patients with COVID-19 admitted to the ICU, mainly consisting of acute pulmonary embolism, deep vein thrombosis, ischemic stroke, myocardial infarction, and systemic arterial embolism. 53 

Despite timely intervention and favorable reperfusion, the mortality rate in COVID-19 with LVO was high in our series and higher in the pooled analysis. Younger age group, the involvement of both the arterial and venous vasculature, multivessel involvement, and complicated procedures due to the clot consistency and burden are notable features. The virus, through direct and indirect factors, creates a milieu that is proischemic and inhibits neuroprotective factors.

. Conception or design of the work: AS, SIT, PJ. 

The relevant anonymized patient-level data are available via request from the authors.

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jabbour is a consultant for Medtronic and MicroVention. Tjoumakaris and Gooch are a consultant for Stryker. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

All procedures performed in the studies involving human participants were per the ethical standards of the Institutional Review Board or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

The author(s) received no financial support for the research, authorship, and/or publication of this article.

The study protocol was reviewed and approved by the Thomas Jefferson University Institutional Review Board. Following our institutional guidelines, all protected health information was removed, and individual patient consent was not required for the analysis of this case series.

Pascal Jabbour https://orcid.org/0000-0002-8965-2413

COVID-19: towards controlling of a pandemic

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

SARS2-CoV-2 and stroke in a New York Healthcare System

Large-vessel stroke as a presenting feature of covid-19 in the young

Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics

Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature

Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris

Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke

COVID-19 presenting as stroke

Neurologic features in severe SARS-CoV-2 infection

Lessons learned over more than 500 stroke thrombectomies using ADAPT with increasing aspiration catheter size

Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial

Endothelial cell infection and endotheliitis in COVID-19

Targeting potential drivers of COVID-19: neutrophil extracellular traps

Acute pulmonary embolism in COVID-19 related hypercoagulability

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis?

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Stroke in patients with SARS-CoV-2 infection: case series

Characteristics of ischaemic stroke associated with COVID-19

Anosmia and ageusia are emerging as symptoms in patients with COVID-19: what does the current evidence say?

Cerebrovascular disease in COVID-19

Cerebral venous sinus thrombosis as a presentation of COVID-19

Acute ischemic stroke complicating common carotid artery thrombosis during a severe COVID-19 infection

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans

Inflammation in neuroviral diseases

Sudden and complete olfactory loss function as a possible symptom of COVID-19

Pathogenetic mechanisms of severe acute respiratory syndrome

Activation of human monocytes after infection by human coronavirus 229E

In vitro detection of apoptosis in monocytes/ macrophages infected with human coronavirus

Cells of human aminopeptidase N (CD13) transgenic mice are infected by human coronavirus-229E in vitro, but not in vivo

Sars-Cov-2: underestimated damage to nervous system

ACE2: from vasopeptidase to SARS virus receptor

Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas

Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors

Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor

Angiotensin-(1-7) inhibits vascular smooth muscle cell growth

Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats

ACE2/ANG-(1-7)/ Mas pathway in the brain: the axis of good

Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway

Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats

Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke

Angiotensin-converting enzyme 2 protects from severe acute lung failure

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

COVID-19 and the cardiovascular system

Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

COVID-19: consider cytokine storm syndromes and immunosuppression

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis